789 related articles for article (PubMed ID: 29463031)
21. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Pompili L; Leonetti C; Biroccio A; Salvati E
J Exp Clin Cancer Res; 2017 Dec; 36(1):189. PubMed ID: 29273061
[TBL] [Abstract][Full Text] [Related]
23. Inter-telomeric recombination is present in telomerase-positive human cells.
Dlaska M; Schöffski P; Bechter OE
Cell Cycle; 2013 Jul; 12(13):2084-99. PubMed ID: 23759591
[TBL] [Abstract][Full Text] [Related]
24. [Telomere Recombination in Normal Mammalian Cells].
Zhdanova NS; Rubtsov NB
Genetika; 2016 Jan; 52(1):14-23. PubMed ID: 27183789
[TBL] [Abstract][Full Text] [Related]
25. Use of U-STELA for Accurate Measurement of Extremely Short Telomeres.
Serakinci N; Cagsin H; Mavis M
Methods Mol Biol; 2019; 2045():217-224. PubMed ID: 29542055
[TBL] [Abstract][Full Text] [Related]
26. The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells.
Feng X; Luo Z; Jiang S; Li F; Han X; Hu Y; Wang D; Zhao Y; Ma W; Liu D; Huang J; Songyang Z
J Cell Sci; 2013 Sep; 126(Pt 17):3982-9. PubMed ID: 23813958
[TBL] [Abstract][Full Text] [Related]
27. New twists to the ALTernative endings at telomeres.
Bhargava R; Lynskey ML; O'Sullivan RJ
DNA Repair (Amst); 2022 Jul; 115():103342. PubMed ID: 35588569
[TBL] [Abstract][Full Text] [Related]
28. Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction.
Xue Y; Li L; Zhang D; Wu K; Chen Y; Zeng J; Wang X; He D
PLoS One; 2011; 6(11):e27748. PubMed ID: 22110753
[TBL] [Abstract][Full Text] [Related]
29. Alternative Lengthening of Telomeres and Mediated Telomere Synthesis.
Hou K; Yu Y; Li D; Zhang Y; Zhang K; Tong J; Yang K; Jia S
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565323
[TBL] [Abstract][Full Text] [Related]
30. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
Gao J; Pickett HA
Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
[TBL] [Abstract][Full Text] [Related]
31. Effect of silencing key proteins in telomerase mechanism and alternative lengthening of telomeres mechanism in laryngeal cancer cells.
Xu Y; Wang X; Chen SM; Chen C; Wang Y; Xiao BK; Tao ZZ
Am J Otolaryngol; 2016; 37(6):552-558. PubMed ID: 27726944
[TBL] [Abstract][Full Text] [Related]
32. The human CTC1/STN1/TEN1 complex regulates telomere maintenance in ALT cancer cells.
Huang C; Jia P; Chastain M; Shiva O; Chai W
Exp Cell Res; 2017 Jun; 355(2):95-104. PubMed ID: 28366536
[TBL] [Abstract][Full Text] [Related]
33. Telomere recombination and alternative telomere lengthening mechanisms.
Draskovic I; Londono Vallejo A
Front Biosci (Landmark Ed); 2013 Jan; 18(1):1-20. PubMed ID: 23276906
[TBL] [Abstract][Full Text] [Related]
34. Resolving Roadblocks to Telomere Replication.
Mason-Osann E; Gali H; Flynn RL
Methods Mol Biol; 2019; 1999():31-57. PubMed ID: 31127568
[TBL] [Abstract][Full Text] [Related]
35. In perspective: An update on telomere targeting in cancer.
Sugarman ET; Zhang G; Shay JW
Mol Carcinog; 2019 Sep; 58(9):1581-1588. PubMed ID: 31062416
[TBL] [Abstract][Full Text] [Related]
36. Timeless protection of telomeres.
Gadaleta MC; González-Medina A; Noguchi E
Curr Genet; 2016 Nov; 62(4):725-730. PubMed ID: 27068713
[TBL] [Abstract][Full Text] [Related]
37. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract][Full Text] [Related]
38. TRF1 phosphorylation on T271 modulates telomerase-dependent telomere length maintenance as well as the formation of ALT-associated PML bodies.
Ho A; Wilson FR; Peragine SL; Jeyanthan K; Mitchell TR; Zhu XD
Sci Rep; 2016 Nov; 6():36913. PubMed ID: 27841304
[TBL] [Abstract][Full Text] [Related]
39. Telomere Length Dynamics and the Evolution of Cancer Genome Architecture.
Cleal K; Norris K; Baird D
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29415479
[TBL] [Abstract][Full Text] [Related]
40. Single-Molecule Telomere Assay via Optical Mapping (SMTA-OM) Can Potentially Define the ALT Positivity of Cancer.
Raseley K; Jinwala Z; Zhang D; Xiao M
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
